half yearly, gsk fim and strategic alliances, page-42

Highly unlikely Pman due to the fact that the FMCG have already tested the technology and if they had known that it wasn't effective then why would they then continue to develop this product from their own pockets? Taking 4 years to date developing the product which is only one key therapeutic agent? Also the fact that the statement of intent sets out the terms and conditions for an agreement also adds more weight to this relationship. Of course this agreement isn't a 100% definite prospect but a fallout is highly unlikely and as always DYOR